-
Je něco špatně v tomto záznamu ?
The time is now: Achieving FH paediatric screening across Europe - The Prague Declaration
N. Bedlington, M. Abifadel, B. Beger, M. Bourbon, H. Bueno, R. Ceska, K. Cillíková, Z. Cimická, M. Daccord, C. de Beaufort, KI. Dharmayat, BA. Ference, T. Freiberger, M. Geanta, SS. Gidding, U. Grošelj, M. Halle, N. Johnson, T. Novakovic, O....
Status neindexováno Jazyk angličtina Země Německo
Typ dokumentu časopisecké články, přehledy
PubMed
36311985
DOI
10.3205/hta000136
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Familial hypercholesterolaemia (FH) is the most common inherited metabolic disorder characterized by high cholesterol and if left untreated leads to premature cardiovascular disease, such as heart attacks. Treatment that begins early in life, particularly in childhood, is highly efficacious in preventing cardiovascular disease and cost-effective, thus early detection of FH is crucial. However, in Europe, less than 10% of people living with FH are diagnosed and even less receive life-saving treatment. The Prague Declaration is a call to action for national and European Union policymakers and decision-makers and a result of the Czech EU Presidency meeting on FH Paediatric Screening (early detection of inherited high cholesterol) at the Czech Senate in Prague on 6th September 2022. It builds on a considerable body of evidence which was discussed at the Technical Meeting under the auspices of the Slovenian EU Presidency in October 2021. The Prague meeting addressed the outstanding barriers to the systematic implementation of FH paediatric screening across Europe. In this article, we present the key points from the Prague meeting and concrete actions needed to move forward.
1st Faculty of Medicine Charles University Prague Czech Rep
3rd Department of Internal Medicine General Teaching Hospital Prague Czech Rep
Basque Foundation for Health Innovation and Research Barakaldo Spain
Cardiology Department Hospital Universitario 12 de Octubre Madrid Spain
Cardiovascular Department CCUL CAML Lisbon School of Medicine University of Lisbon Lisbon Portugal
Centre for Cardiovascular Surgery and Transplantation Brno Czech Rep
Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares Madrid Spain
Centro Nacional de Investigaciones Cardiovasculares Madrid Spain
Department of Cardiology Hacettepe University Ankara Turkey
Deutsches Herzzentrum München Munich Germany
Deutsches Zentrum für Herz Kreislauf Forschung Munich Heart Alliance Munich Germany
Diabetes and Endocrine Care Clinique Pediatrique CHL Luxembourg Grand Duchy Luxembourg
Europan Public Health Alliance Brussels Belgium
European Atherosclerosis Society Göteborg Sweden
European Heart Network European Alliance for Cardiovascular Health Brussels Belgium
Facultad de Medicina Universidad Complutense de Madrid Madrid Spain
Faculty of Medicine University of Ljubljana Ljubljana Slovenia
FH Europe Star House Rochester UK
Global Heart Hub Galway Ireland
Hospital Israelita Albert Einstein Sao Paulo Brazil
Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Rep
Instituto de Investigación Sanitaria Hospital 12 de Octubre Madrid Spain
International Atherosclerosis Society Milan Italy
Laboratory for Vascular Translational Science Paris Cité University Paris France
Lipid Clinic Heart Institute University of Sao Paulo Medical School Hospital Sao Paulo Brazil
Medical Faculty Masaryk University Brno Czech Rep
Sorbonne Paris Nord University INSERM Paris France
The Digital Health Society Dublin Ireland
The European Connected Health Alliance Belfast UK
University Hospital Center Zagreb Department for Metabolic Diseases Zagreb Croatia
University of Amsterdam Department of Paediatrics Amsterdam Netherlands
University Of Cambridge Clinical School Cambridge UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22031637
- 003
- CZ-PrNML
- 005
- 20230127131241.0
- 007
- ta
- 008
- 230119s2022 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3205/hta000136 $2 doi
- 035 __
- $a (PubMed)36311985
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Bedlington, Nicole $u FH Europe, Star House, Rochester, UK
- 245 14
- $a The time is now: Achieving FH paediatric screening across Europe - The Prague Declaration / $c N. Bedlington, M. Abifadel, B. Beger, M. Bourbon, H. Bueno, R. Ceska, K. Cillíková, Z. Cimická, M. Daccord, C. de Beaufort, KI. Dharmayat, BA. Ference, T. Freiberger, M. Geanta, SS. Gidding, U. Grošelj, M. Halle, N. Johnson, T. Novakovic, O. Májek, A. Pallidis, N. Peretti, FJ. Pinto, KK. Ray, B. Rees, J. Reeve, Ž. Reiner, RD. Santos, H. Schunkert, J. Šikonja, M. Sokolovic, L. Tokgözoglu, M. Vrablík, A. Wiegman, I. Gutiérrez-Ibarluzea
- 520 9_
- $a Familial hypercholesterolaemia (FH) is the most common inherited metabolic disorder characterized by high cholesterol and if left untreated leads to premature cardiovascular disease, such as heart attacks. Treatment that begins early in life, particularly in childhood, is highly efficacious in preventing cardiovascular disease and cost-effective, thus early detection of FH is crucial. However, in Europe, less than 10% of people living with FH are diagnosed and even less receive life-saving treatment. The Prague Declaration is a call to action for national and European Union policymakers and decision-makers and a result of the Czech EU Presidency meeting on FH Paediatric Screening (early detection of inherited high cholesterol) at the Czech Senate in Prague on 6th September 2022. It builds on a considerable body of evidence which was discussed at the Technical Meeting under the auspices of the Slovenian EU Presidency in October 2021. The Prague meeting addressed the outstanding barriers to the systematic implementation of FH paediatric screening across Europe. In this article, we present the key points from the Prague meeting and concrete actions needed to move forward.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Abifadel, Marianne $u Laboratory of Biochemistry & Molecular Therapeutics, Faculty of Pharmacy, Pôle Technologie-Santé, Saint Joseph University of Beirut, Beirut, Lebanon $u Laboratory for Vascular Translational Science, Paris Cité University, Paris, France $u Sorbonne Paris Nord University, INSERM, Paris, France
- 700 1_
- $a Beger, Birgit $u European Heart Network, European Alliance for Cardiovascular Health, Brussels, Belgium
- 700 1_
- $a Bourbon, Mafalda $u Unidade de I&D, Grupo de Investigação Cardiovascular, Departamento de Promoção da Saúde e Prevenção de Doenças Não Transmissíveis, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisboa, Portugal $u BioISI - Biosystems & Integrative Sciences Institute, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal
- 700 1_
- $a Bueno, Héctor $u Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain $u Cardiology Department, Hospital Universitario 12 de Octubre, Madrid, Spain $u Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain $u Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares, Madrid, Spain $u Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
- 700 1_
- $a Ceska, Richard $u 3rd Department of Medicine - Department of Endocrinology & Metabolism of the 1st Faculty of Medicine, Charles University & General University Hospital, Prague, Czech Rep
- 700 1_
- $a Cillíková, Kristýna $u Diagnoza FH, Libáň, Czech Rep
- 700 1_
- $a Cimická, Zdenka $u Diagnoza FH, Libáň, Czech Rep
- 700 1_
- $a Daccord, Magdalena $u FH Europe, Star House, Rochester, UK
- 700 1_
- $a de Beaufort, Carine $u Diabetes & Endocrine Care Clinique Pediatrique/CHL, Luxembourg, Grand Duchy Luxembourg
- 700 1_
- $a Dharmayat, Kanika I $u Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London, UK
- 700 1_
- $a Ference, Brian A $u University Of Cambridge, Clinical School, Cambridge, UK
- 700 1_
- $a Freiberger, Tomáš $u Centre for Cardiovascular Surgery and Transplantation, Brno, Czech Rep $u Medical Faculty, Masaryk University, Brno, Czech Rep
- 700 1_
- $a Geanta, Marius $u FH Europe, Star House, Rochester, UK
- 700 1_
- $a Gidding, Samuel S $u FH Europe, Star House, Rochester, UK
- 700 1_
- $a Grošelj, Urh $u Department of Endocrinology, Diabetes & Metabolic Diseases, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia $u Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- 700 1_
- $a Halle, Martin $u Department of Prevention & Sports Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, Munich, Germany $u Deutsches Zentrum für Herz-Kreislauf-Forschung, Munich Heart Alliance, Munich, Germany
- 700 1_
- $a Johnson, Neil $u Global Heart Hub, Galway, Ireland
- 700 1_
- $a Novakovic, Tanja $u ZEM Solutions Ltd, Belgrade, Serbia
- 700 1_
- $a Májek, Ondrej $u National Screening Centre, Institute of Health Information & Statistics of the Czech Republic, Prague, Czech Rep $u Institute of Biostatistics & Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Rep
- 700 1_
- $a Pallidis, Athanasios $u LDL Greece, Athens, Greece
- 700 1_
- $a Peretti, Noel $u Department of Pediatric Gastroenterology-Hepatology & Nutrition, Hospices Civil de Lyon HCL, Hôpital Femme Mere Enfant HFME, Bron, France $u Univ-Lyon, CarMeN laboratory, INSERM U1060, INRAE U1397, Université Claude Bernard Lyon-1, Oullins, Lyon, France
- 700 1_
- $a Pinto, Fausto J $u World Heart Federation, Geneva, Switzerland $u Cardiovascular Department, CCUL, CAML, Lisbon School of Medicine, University of Lisbon, Lisbon, Portugal
- 700 1_
- $a Ray, Kausik Kosh $u Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London, UK $u European Atherosclerosis Society, Göteborg, Sweden
- 700 1_
- $a Rees, Bleddyn $u The Digital Health Society, Dublin, Ireland $u The European Connected Health Alliance, Belfast, UK
- 700 1_
- $a Reeve, John $u FH Europe, Star House, Rochester, UK
- 700 1_
- $a Reiner, Željko $u University Hospital Center Zagreb, Department for Metabolic Diseases, Zagreb, Croatia
- 700 1_
- $a Santos, Raul D $u Lipid Clinic Heart Institute, University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil $u Hospital Israelita Albert Einstein, Sao Paulo, Brazil $u International Atherosclerosis Society, Milan, Italy
- 700 1_
- $a Schunkert, Heribert $u Deutsches Herzzentrum München, Munich, Germany
- 700 1_
- $a Šikonja, Jaka $u Department of Endocrinology, Diabetes & Metabolic Diseases, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia
- 700 1_
- $a Sokolovic, Milka $u Europan Public Health Alliance, Brussels, Belgium
- 700 1_
- $a Tokgözoglu, Lale $u Department of Cardiology, Hacettepe University, Ankara, Turkey $u European Atherosclerosis Society, Göteborg, Sweden
- 700 1_
- $a Vrablík, Michal $u 3rd Department of Internal Medicine, General Teaching Hospital, Prague, Czech Rep $u 1st Faculty of Medicine, Charles University, Prague, Czech Rep
- 700 1_
- $a Wiegman, Albert $u University of Amsterdam, Department of Paediatrics, Amsterdam, Netherlands
- 700 1_
- $a Gutiérrez-Ibarluzea, Iñaki $u Basque Foundation for Health Innovation and Research, Barakaldo, Spain
- 773 0_
- $w MED00210147 $t GMS health innovation and technologies $x 2698-6388 $g Roč. 16, č. - (2022), s. Doc04
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36311985 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230119 $b ABA008
- 991 __
- $a 20230127131233 $b ABA008
- 999 __
- $a ok $b bmc $g 1889582 $s 1182970
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2022 $b 16 $c - $d Doc04 $e 20220930 $i 2698-6388 $m GMS health innovation and technologies $n GMS Health Innov Technol $x MED00210147
- LZP __
- $a Pubmed-20230119
